Negative Effects of Latent Toxoplasmosis on Mental Health
Infection by the parasite Toxoplasma, which affects about 33% of world population, is associated with an increased risk of several mental health disorders, the most strongly with schizophrenia. It is unknown whether schizophrenia is associated with this infection the most strongly, or whether this association has just been the most intensively studied for historical reasons. We used the data from 6,367 subjects tested for toxoplasmosis who took part in an internet survey to search for associations of these infections with 24 mental health disorders and evidence of otherwise impaired mental health. The typical symptom associated with toxoplasmosis was anxiety, and the typical toxoplasmosis-associated disorders were autism (OR = 4.78), schizophrenia (OR = 3.33), attention deficit hyperactivity disorder (OR = 2.50), obsessive compulsive disorder (OR = 1.86), antisocial personality disorder (OR = 1.63), learning disabilities (OR = 1.59), and anxiety disorder (OR = 1.48). Toxoplasmosis could play a substantial role in the etiopathogenesis of mental health disorders and its association with schizophrenia is the second strongest association, after autism.
Publication date: Available online 27 March 2020Source: Neuroimaging Clinics of North AmericaAuthor(s): Heather L. Green, J. Christopher Edgar, Junko Matsuzaki, Timothy P.L. Roberts
Publication date: Available online 28 March 2020Source: Mental Health and Physical ActivityAuthor(s): Kristen M. Lucibello, Emily M. Paolucci, Jeffrey D. Graham, Jennifer J. Heisz
Publication date: Available online 28 March 2020Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): N.K. Schaal, P. Hepp, M. Heil, O.T. Wolf, C. Hagenbeck, M. Fleisch, T. Fehm
Conclusion: CoBaT-Y017, a Phase II study was conducted with Plasmodium falciparum malaria-infected patients, for efficacy and safety evaluation of CoBaT-Y017 compared with Artemether-Lumefantrine used as a positive control. Methods. A single-blind randomized trial was conducted on 25 eligible males aged 18-40 years randomly assigned to two treatment groups: CoBaT-Y017 or Artemether-Lumefantrine. The first group received 35 ml of CoBaT-Y017 in 1.5 L mineral water administered daily for four consecutive days; the second group received oral Artemether-Lumefantrine, using WHO-recommended therapeutic dose regimens...
Survey results show COVID-19 is affecting many Americans'mental health, which is not surprising. But one expert warns that if the pandemic goes on much longer anxiety levels could become much worse.Medscape Medical News
Publication date: June 2020Source: Research in Developmental Disabilities, Volume 101Author(s): Rabya Mughal, Anna Joyce, Catherine Hill, Dagmara Dimitriou
Dr. Zeyad Baker thought he was pretty proactive and thorough in thinking through how his team of doctors, nurses, nurse practitioners, physician assistants and medical assistants could address the surging number of cases of COVID-19 cases in New York. The president and CEO of ProHEALTH, a group of 1,000 independent clinicians, took the doctors and nurses who were no longer seeing patients for non-essential visits, and reassigned them to evaluate people coming in with COVID-19 symptoms. He turned the driveways of a few of the ProHEALTH centers into drive-thru COVID-19 testing centers, and worked with doctors and nurses to a...
The psychological factors that reduce the chance of infection. → Support PsyBlog for just $5 per month. Enables access to articles marked (M) and removes ads. → Explore PsyBlog's ebooks, all written by Dr Jeremy Dean: Accept Yourself: How to feel a profound sense of warmth and self-compassion The Anxiety Plan: 42 Strategies For Worry, Phobias, OCD and Panic Spark: 17 Steps That Will Boost Your Motivation For Anything Activate: How To Find Joy Again By Changing What You Do
Publication date: Available online 27 March 2020Source: NeuroscienceAuthor(s): Roberta De Simone, Alessia Butera, Monica Armida, Antonella Pezzola, Monica Boirivant, Rosa Luisa Potenza, Laura Ricceri
CONCLUSIONS: We report a fetus with Kabuki syndrome 2 detected using CMA. It is strongly recommended that CMA be included in prenatal diagnosis in fetuses with growth retardation, cardiovascular and musculoskeletal abnormalities revealed by routine Color Doppler ultrasonography. PMID: 32211113 [PubMed]